Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.70 |
| ▸ | NTRK3 | Q16288 | 7/20 | 0.70 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.70 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.70 |
| ▸ | DDR1 | Q08345 | 6/20 | 0.57 |
| ▸ | DDR2 | Q16832 | 5/20 | 0.57 |
| ▸ | ABL2 | P42684 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | STK10 | O94804 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.53 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
| ▸ | EPHA7 | Q15375 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144984 | 0.93 | ABL1 (0.70) | ABL1NTRK3NTRK1NTRK2DDR1 | |
| SCHEMBL9611053 | 0.92 | ABL1 (0.69) | ABL1NTRK3NTRK1NTRK2DDR1 | |
| SCHEMBL10207568 | 0.90 | ABL1 (0.79) | ABL1NTRK3NTRK1NTRK2DDR1 | |
| SCHEMBL10207524 | 0.89 | ABL1 (0.79) | ABL1NTRK3NTRK1NTRK2DDR1 | |
| SCHEMBL15061738 | 0.85 | ABL1 (0.77) | ABL1NTRK3NTRK1NTRK2DDR1 | |
| SCHEMBL15061730 | 0.82 | ABL1 (0.68) | ABL1NTRK3NTRK1NTRK2ABL2 | |
| SCHEMBL21843620 | 0.82 | ABL1 (0.78) | ABL1NTRK3NTRK1NTRK2DDR1 | |
| SCHEMBL31474781 | 0.82 | ABL1 (0.78) | ABL1NTRK3NTRK1NTRK2DDR1 | |
| SCHEMBL15871945 | 0.81 | ABL1 (0.66) | ABL1NTRK3NTRK1NTRK2ABL2 | |
| SCHEMBL10207561 | 0.81 | ABL1 (0.80) | ABL1NTRK3NTRK1NTRK2ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2020-07-23 | — | — | US | disclosed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ABL1 2649/4885NTRK3 2316/4885NTRK1 4165/4885 |
| US-20200231588-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885NTRK3 2458/4885NTRK1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.